Pierre Fabre Medicament

Institut Pasteur

Ecole Nationale Veterinaire D'alfort

L'assistance Publique - Hopitaux De Paris

Pathoquest

Pathquest

Assistance Publique-hopitaux De Paris

Jean Deregnaucourt

Richard Grosse

Marc Eloit

Philippe Perot

Isabelle Heard

Nicolas Torno

Marion Mouton

Jacky Tisne-Versailles

Etienne Andre

The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.

Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus-associated cancer stages

The present invention concerns the use of a mixture of enantiomers enriched in the dextrogyral enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts, for the preparation of a drug intended to prevent or to treat disorders that can be managed by double inhibition of serotonin (5-HT) and norepinephrine (NE) reuptake, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity.

Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug

The present invention relates to the use of at least one antihistamine agent for the preparation of a medicament for use in the preventive or early treatment of inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. The invention also relates to a combination product of at least one antihistamine agent and of at least one antiserotonin agent for its simultaneous, separate or sequential use in preventive or early therapy for inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses.

Use of antihistamine agents for the preventive or early treatment of inflammatory syndromes, in particular those triggered by togaviruses

A method for treating or preventing a disorder or a condition by double inhibition of serotonin (5-HT) and noradrenaline (NA) reuptake in a subject in need thereof, while limiting the risks of cardiovascular disturbances and/or organ and/or tissue toxicity, comprising the step of administering to said subject a mixture of enantiomers of milnacipran enriched in the (1S,2R) enantiomer of milnacipran and/or of at least one of its metabolites, as well as their pharmaceutically-acceptable salts.

Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug

Growing community of inventors

Paris, France

Jean Deregnaucourt